April L. Lukowski

April L. Lukowski

Auto-generated profile, based on publicly available information

April L. Lukowski

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2017 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
SDSummer A. Baker Dockrey
Summer A. Baker Dockrey
ALApril L. Lukowski
April L. Lukowski
MBMarc R. Becker
Marc R. Becker
ANAlison R. H. Narayan
Alison R. H. Narayan

7 September 2018 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
ALApril L. Lukowski
April L. Lukowski
DEDuncan C. Ellinwood
Duncan C. Ellinwood
MHMeagan E. Hinze
Meagan E. Hinze
RDRyan J. DeLuca
Ryan J. DeLuca
JBJ. Du Bois
J. Du Bois
ANAlison R. H. Narayan
Alison R. H. Narayan

15 April 2019 in ACS Chemical Biology
Verified
Journal Article
Open access
ALApril L. Lukowski
April L. Lukowski
NDNicholas Denomme
Nicholas Denomme
MHMeagan E. Hinze
Meagan E. Hinze
SHSherwood Hall
Sherwood Hall
LILori L. Isom
Lori L. Isom
ANAlison R. H. Narayan
Alison R. H. Narayan
Small molecules that bind to voltage-gated sodium channels (VGSCs) are promising leads in the treatment of numerous neurodegenerative diseases and pain. Nature is a highly skilled medicinal chemist in this regard, designing potent VGSC ligands capable of binding to and blocking the channel, thereby offering compounds of potential therapeutic interest. Paralytic shellfish toxins (PSTs), produced by cyanobacteria and marine dinoflagellates, are examples of these naturally occurring small molecule VGSC blockers that can potentially be leveraged to solve human health concerns. Unfortunately, the remarkable potency of these natural products results in equally exceptional toxicity, presenting a significant challenge for the therapeutic application of these compounds. Identifying less potent analogs and convenient methods for accessing them therefore provides an attractive approach to developing molecules with enhanced therapeutic potential. Fortunately, Nature has evolved tools to modulate the toxicity of PSTs through selective hydroxylation, sulfation, and desulfation of the core scaffold. Here, we demonstrate the function of enzymes encoded in cyanobacterial PST biosynthetic gene clusters that have evolved specifically for the sulfation of highly functionalized PSTs, the substrate scope of these enzymes, and elucidate the biosynthetic route from saxitoxin to monosulfated gonyautoxins and disulfated C-toxins. Finally, the binding affinities of the nonsulfated, monosulfated, and disulfated products of these enzymatic reactions have been evaluated for VGSC binding affinity using mouse whole brain membrane preparations to provide an assessment of relative toxicity. These data demonstrate the unique detoxification effect of sulfotransferases in PST biosynthesis, providing a potential mechanism for the development of more attractive PST-derived therapeutic analogs.

25 March 2019 in ACS Catalysis
Verified
Journal Article
Closed access
ABAttabey Rodríguez Benítez
Attabey Rodríguez Benítez
STSara E. Tweedy
Sara E. Tweedy
SDSummer A. Baker Dockrey
Summer A. Baker Dockrey
ALApril L. Lukowski
April L. Lukowski
TWTroy Wymore
Troy Wymore
ANAlison R. H. Narayan
Alison R. H. Narayan

18 August 2023 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
ALApril L. Lukowski
April L. Lukowski
FHFelix M. Hubert
Felix M. Hubert
TNThuan-Ethan Ngo
Thuan-Ethan Ngo
NANicole Avalon
Nicole Avalon
WGWilliam Gerwick
William Gerwick
BMBradley S. Moore
Bradley S. Moore

16 September 2024 in Nature Chemistry
Verified
Journal Article
Open access
SASanjoy Adak
Sanjoy Adak
NYNaike Ye
Naike Ye
LCLogan A. Calderone
Logan A. Calderone
MDMeng Duan
Meng Duan
WLWilson Lubeck
Wilson Lubeck
BMBradley S. Moore
Bradley S. Moore
Nitriles are uncommon in nature and are typically constructed from oximes through the oxidative decarboxylation of amino acid substrates or from the derivatization of carboxylic acids. Here we report a third nitrile biosynthesis strategy featuring the cyanobacterial nitrile synthase AetD. During the biosynthesis of the eagle-killing neurotoxin, aetokthonotoxin, AetD transforms the 2-aminopropionate portion of 5,7-dibromo-l-tryptophan to a nitrile. Employing a combination of structural, biochemical and biophysical techniques, we characterized AetD as a non-haem diiron enzyme that belongs to the emerging haem-oxygenase-like dimetal oxidase superfamily. High-resolution crystal structures of AetD together with the identification of catalytically relevant products provide mechanistic insights into how AetD affords this unique transformation, which we propose proceeds via an aziridine intermediate. Our work presents a unique template for nitrile biogenesis and portrays a substrate binding and metallocofactor assembly mechanism that may be shared among other haem-oxygenase-like dimetal oxidase enzymes.